mProX™ Human B2M Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human B2M Stable Cell Line (S01YF-1023-PY189). Click the button above to contact us or submit your feedback about this product.
Skyler Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jordan Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The outcome of immunotherapy can be influenced by the modulation of B2M expression.
The validation of B2M knockdown in MC38 cells (MC38-shB2M) was confirmed through FACS analysis following lentivirus shRNA infection. Subsequent treatment with α-PD-L1 or PBS was administered to mice harboring MC38-shB2M or MC38-shNS control tumors.
Ref: Zhao, Yu, et al. "B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy." Immunology 164.3 (2021): 507-523.
Pubmed: 34115389
DOI: 10.1111/imm.13384
Research Highlights
Hyun Lee, Dong. et al. "CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents." Molecular oncology, 2023.
The importance of identifying chemotherapeutic agents that produce the strongest anti-tumor senescence (TIS) is crucial, as TIS can either support or inhibit cancer progression. In this study, the researchers compared the TIS induced by conventional DNA-damaging agents to that induced by cyclin-dependent kinase4/6 inhibitors (CDK4/6i). Although both types of agents resulted in a similar degree of senescence, the TIS induced by DNA-damaging agents showed increased expression of pro-tumor immunity and angiogenesis-related proteins. Conversely, CDK4/6i-induced senescent cells maintained high expression of anti-tumor immunomodulatory proteins, despite the absence of nuclear factor-kappa-B (NF-κB) and p53 activation. These findings suggest that CDK4/6i primarily generates TIS with immunomodulatory proteins, whereas DNA-damaging agents contribute to a pro-tumorigenic microenvironment through SASP.
Hyun Lee, Dong. et al. "CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents." Molecular oncology, 2023.
Pubmed:
37854019
DOI:
10.1002/1878-0261.13541
Hu, Yang. et al. "Screening and validation of the optimal panel of reference genes in colonic epithelium and relative cancer cell lines." Scientific reports, 2023.
This study conducted an investigation into identifying the most suitable reference genes for Real-time quantitative polymerase chain reaction (RT-qPCR) experiments in colorectal cancer (CRC) and normal colonic cell lines. Eight candidate reference genes were examined across various cell lines, and their stability was assessed using geNorm, NormFinder, and BestKeeper software. The results revealed that the optimal panel of reference genes varied among the cell lines, with YWHAZ + B2M being ideal for NCM460, HCT116, SW620, LOVO, RKO, SW480, and HT29 cell lines, while PPIA + GUSB was found to be optimal for DLD-1 cell lines.
Hu, Yang. et al. "Screening and validation of the optimal panel of reference genes in colonic epithelium and relative cancer cell lines." Scientific reports, 2023.
Pubmed:
37853035
DOI:
10.1038/s41598-023-45174-4
